These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6417315)

  • 1. Desensitization of gonadotropin-releasing response following vaginal consecutive administration of leuprolide in rats.
    Okada H; Yamazaki I; Sakura Y; Yashiki T; Shimamoto T; Mima H
    J Pharmacobiodyn; 1983 Jul; 6(7):512-22. PubMed ID: 6417315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats. IV: Evaluation of the vaginal absorption and gonadotropin responses by radioimmunoassay.
    Okada H; Yamazaki I; Yashiki T; Shimamoto T; Mima H
    J Pharm Sci; 1984 Mar; 73(3):298-302. PubMed ID: 6425491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of rat mammary tumors by a potent luteinizing hormone-releasing hormone analogue (leuprolide) administered vaginally.
    Okada H; Sakura Y; Kawaji H; Yashiki T; Mima H
    Cancer Res; 1983 Apr; 43(4):1869-74. PubMed ID: 6403230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats II: mechanism of absorption enhancement with organic acids.
    Okada H; Yamazaki I; Yashiki T; Mima H
    J Pharm Sci; 1983 Jan; 72(1):75-8. PubMed ID: 6402584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats I: absorption by various routes and absorption enhancement.
    Okada H; Yamazaki I; Ogawa Y; Hirai S; Yashiki T; Mima H
    J Pharm Sci; 1982 Dec; 71(12):1367-71. PubMed ID: 6818337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats III: Effect of estrous cycle on vaginal absorption of hydrophilic model compounds.
    Okada H; Yashiki T; Mima H
    J Pharm Sci; 1983 Feb; 72(2):173-6. PubMed ID: 6403693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms involved in the pituitary desensitization induced by gonadotropin-releasing hormone agonists.
    Uemura T; Yanagisawa T; Shirasu K; Matsuyama A; Minaguchi H
    Am J Obstet Gynecol; 1992 Jul; 167(1):283-91. PubMed ID: 1332475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum concentration patterns of an LHRH agonist, gonadotrophins and sex steroids after subcutaneous, vaginal, rectal and nasal administration of the agonist to pregnant rats.
    Yamazaki I
    J Reprod Fertil; 1984 Sep; 72(1):129-36. PubMed ID: 6433008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer.
    Wojciechowski NJ; Carter CA; Skoutakis VA; Bess DT; Falbe WJ; Mickle TR
    Drug Intell Clin Pharm; 1986 Oct; 20(10):746-51. PubMed ID: 2429815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential actions of a mammalian gonadotropin-releasing hormone antagonist on gonadotropin-II and growth hormone release in goldfish, Carassius auratus.
    Murthy CK; Turner RJ; Wong AO; Rao PD; Rivier JE; Peter RE
    Neuroendocrinology; 1994 Jun; 59(6):561-71. PubMed ID: 8084380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of intermittent and continuous use of a gonadotropin-releasing hormone antagonist (Nal-Glu) in in vitro fertilization cycles: a preliminary report.
    Cassidenti DL; Sauer MV; Paulson RJ; Ditkoff EC; Rivier J; Yen SS; Lobo RA
    Am J Obstet Gynecol; 1991 Dec; 165(6 Pt 1):1806-10. PubMed ID: 1750479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a superactive luteinizing hormone-releasing factor agonist on gonadotropin and ovarian function during the menstrual cycle.
    Sheehan KL; Casper RF; Yen SS
    Am J Obstet Gynecol; 1979 Nov; 135(6):759-63. PubMed ID: 386801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of danazol, gonadotropin-releasing hormone agonist, and a combination of danazol and gonadotropin-releasing hormone agonist on experimental endometriosis.
    Sakata M; Terakawa N; Mizutani T; Tanizawa O; Matsumoto K; Terada N; Sudo K
    Am J Obstet Gynecol; 1990 Nov; 163(5 Pt 1):1679-84. PubMed ID: 2122726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
    Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrinological studies on TAP-144-SR, a sustained-release formulation of a potent GnRH agonist (D-Leu6-[des-Gly10-NH2]-GnRH ethylamide), in male rats.
    Sudo K; Masaki T; Shiota K; Kawase M; Fujita T
    Endocrinol Jpn; 1990 Oct; 37(5):685-93. PubMed ID: 2128273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a sustained release formulation of the gonadotrophin-releasing hormone agonist histrelin on serum concentrations of gonadotrophins and oestradiol, and ovarian LH/human chorionic gonadotrophin receptor content in the rat.
    Gunnet JW; Demarest KT; Hahn DW; Ericson E; McGuire JL
    J Endocrinol; 1991 Nov; 131(2):211-8. PubMed ID: 1744568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.
    Warner B; Worgul TJ; Drago J; Demers L; Dufau M; Max D; Santen RJ
    J Clin Invest; 1983 Jun; 71(6):1842-53. PubMed ID: 6408125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term suppression of luteinizing hormone, follicle-stimulating hormone and testosterone by daily administration of leuprolide.
    Glode LM; Smith JA
    J Urol; 1987 Jan; 137(1):57-60. PubMed ID: 3098990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration.
    Dubourdieu S; Charbonnel B; Massai MR; Marraoui J; Spitz I; Bouchard P
    Fertil Steril; 1991 Sep; 56(3):440-5. PubMed ID: 1894021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the suppressive effects of testosterone and a potent new gonadotropin-releasing hormone antagonist on gonadotropin and inhibin levels in normal men.
    Bagatell CJ; McLachlan RI; de Kretser DM; Burger HG; Vale WW; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1989 Jul; 69(1):43-8. PubMed ID: 2499592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.